Revenues of Pharma-Bio Serv, Inc. from 30 Apr 2017 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Pharma-Bio Serv, Inc. quarterly and annual Revenues in USD history and change rate from 30 Apr 2017 to 31 Oct 2025.
  • Pharma-Bio Serv, Inc. Revenues for the quarter ending 31 Oct 2025 was $2,149,636, a 7.9% decline year-over-year.
  • Pharma-Bio Serv, Inc. Revenues for the twelve months ending 31 Oct 2025 was $9,001,096, a 5.3% decline year-over-year.
  • Pharma-Bio Serv, Inc. annual Revenues for 2025 was $9,001,096, a 5.3% decline from 2024.
  • Pharma-Bio Serv, Inc. annual Revenues for 2024 was $9,509,279, a 44% decline from 2023.
  • Pharma-Bio Serv, Inc. annual Revenues for 2023 was $16,976,856, a 12% decline from 2022.
Source SEC data
View on sec.gov
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Change (%)
Revenues, Annual (USD)
Revenues, YoY Annual Change (%)

Pharma-Bio Serv, Inc. Quarterly Revenues (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $9,001,096 $2,149,636 -$183,676 -7.9% 01 Aug 2025 31 Oct 2025 10-K 29 Jan 2026 2025 FY
Q2 2025 $9,184,772 $1,963,083 -$455,080 -19% 01 May 2025 31 Jul 2025 10-Q 15 Sep 2025 2025 Q3
Q1 2025 $9,639,852 $2,417,044 +$39,427 +1.7% 01 Feb 2025 30 Apr 2025 10-Q 16 Jun 2025 2025 Q2
Q4 2024 $9,600,425 $2,471,333 +$91,146 +3.8% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q1
Q3 2024 $9,509,279 $2,333,312 -$1,264,879 -35% 01 Aug 2024 31 Oct 2024 10-K 29 Jan 2026 2025 FY
Q2 2024 $10,774,158 $2,418,163 -$2,159,004 -47% 01 May 2024 31 Jul 2024 10-Q 15 Sep 2025 2025 Q3
Q1 2024 $12,933,162 $2,377,617 -$2,185,525 -48% 01 Feb 2024 30 Apr 2024 10-Q 16 Jun 2025 2025 Q2
Q4 2023 $15,118,687 $2,380,187 -$1,858,169 -44% 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q1
Q3 2023 $16,976,856 $3,598,191 -$1,040,011 -22% 01 Aug 2023 31 Oct 2023 10-K 29 Jan 2025 2024 FY
Q2 2023 $18,016,867 $4,577,167 -$196,936 -4.1% 01 May 2023 31 Jul 2023 10-Q 16 Sep 2024 2024 Q3
Q1 2023 $18,213,803 $4,563,142 -$404,176 -8.1% 01 Feb 2023 30 Apr 2023 10-Q 14 Jun 2024 2024 Q2
Q4 2022 $18,617,979 $4,238,356 -$780,748 -16% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q1
Q3 2022 $19,398,727 $4,638,202 -$959,089 -17% 01 Aug 2022 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q2 2022 $20,357,816 $4,774,103 -$213,806 -4.3% 01 May 2022 31 Jul 2022 10-Q 14 Sep 2023 2023 Q3
Q1 2022 $20,571,622 $4,967,318 -$74,348 -1.5% 31 Jan 2022 30 Apr 2022 10-Q 14 Jun 2022 2022 Q2
Q4 2021 $20,645,970 $5,019,104 +$530,795 +12% 01 Nov 2021 31 Jan 2022 10-Q 17 Mar 2023 2023 Q1
Q3 2021 $20,115,175 $5,597,291 +$572,235 +11% 01 Aug 2021 31 Oct 2021 10-K 30 Jan 2023 2022 FY
Q2 2021 $19,542,940 $4,987,909 -$1,290,461 -21% 01 May 2021 31 Jul 2021 10-Q 14 Sep 2022 2022 Q3
Q1 2021 $20,833,401 $5,041,666 -$606,101 -11% 31 Jan 2021 30 Apr 2021 10-Q 14 Jun 2022 2022 Q2
Q4 2020 $21,439,502 $4,488,309 -$124,858 -2.7% 01 Nov 2020 31 Jan 2021 10-Q 17 Mar 2022 2022 Q1
Q3 2020 $21,564,360 $5,025,056 +$201,205 +4.2% 01 Aug 2020 31 Oct 2020 10-K 11 Feb 2022 2021 FY
Q2 2020 $21,363,155 $6,278,370 +$1,311,851 +26% 01 May 2020 31 Jul 2020 10-Q 14 Sep 2021 2021 Q3
Q1 2020 $20,051,304 $5,647,767 +$497,423 +9.7% 01 Feb 2020 30 Apr 2020 10-Q 14 Jun 2021 2021 Q2
Q4 2019 $19,553,881 $4,613,167 +$46,970 +1% 01 Nov 2019 31 Jan 2020 10-Q 17 Mar 2021 2021 Q1
Q3 2019 $19,506,911 $4,823,851 -$850,317 -15% 01 Aug 2019 31 Oct 2019 10-K 01 Feb 2021 2020 FY
Q2 2019 $20,357,228 $4,966,519 +$335,216 +7.2% 01 May 2019 31 Jul 2019 10-Q 14 Sep 2020 2020 Q3
Q1 2019 $20,022,012 $5,150,344 +$1,384,986 +37% 01 Feb 2019 30 Apr 2019 10-Q 15 Jun 2020 2020 Q2
Q4 2018 $18,637,026 $4,566,197 +$839,601 +23% 01 Nov 2018 31 Jan 2019 10-Q 16 Mar 2020 2020 Q1
Q3 2018 $17,797,425 $5,674,168 01 Aug 2018 31 Oct 2018 10-K 29 Jan 2020 2019 FY
Q2 2018 $4,631,303 +$651,163 +16% 01 May 2018 31 Jul 2018 10-Q 16 Sep 2019 2019 Q3
Q1 2018 $3,765,358 -$155,809 -4% 01 Feb 2018 30 Apr 2018 10-Q 14 Jun 2019 2019 Q2
Q4 2017 $3,726,596 01 Nov 2017 31 Jan 2018 10-Q 18 Mar 2019 2019 Q1
Q2 2017 $3,980,140 01 May 2017 31 Jul 2017 10-Q 14 Sep 2018 2018 Q3
Q1 2017 $3,921,167 01 Feb 2017 30 Apr 2017 10-Q 14 Jun 2018 2018 Q2

Pharma-Bio Serv, Inc. Annual Revenues (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $9,001,096 -$508,183 -5.3% 01 Nov 2024 31 Oct 2025 10-K 29 Jan 2026 2025 FY
2024 $9,509,279 -$7,467,577 -44% 01 Nov 2023 31 Oct 2024 10-K 29 Jan 2026 2025 FY
2023 $16,976,856 -$2,421,871 -12% 01 Nov 2022 31 Oct 2023 10-K 29 Jan 2025 2024 FY
2022 $19,398,727 -$716,448 -3.6% 01 Nov 2021 31 Oct 2022 10-K 29 Jan 2024 2023 FY
2021 $20,115,175 -$1,449,185 -6.7% 01 Nov 2020 31 Oct 2021 10-K 30 Jan 2023 2022 FY
2020 $21,564,360 +$2,057,449 +11% 01 Nov 2019 31 Oct 2020 10-K 11 Feb 2022 2021 FY
2019 $19,506,911 +$1,709,486 +9.6% 01 Nov 2018 31 Oct 2019 10-K 01 Feb 2021 2020 FY
2018 $17,797,425 +$4,499,827 +34% 01 Nov 2017 31 Oct 2018 10-K 29 Jan 2020 2019 FY
2017 $13,297,598 01 Nov 2016 31 Oct 2017 10-K 29 Jan 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.